Twin Peaks Wealth Advisors’s Akebia Therapeutics AKBA Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$33	Buy	+24	New	+$33	﹤0.01%	2326

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Twin Peaks Wealth Advisors's AKBA Position: Q1 2026 in Review

Twin Peaks Wealth Advisors opened a new position in Akebia Therapeutics (AKBA) in Q1 2026: 24 shares worth $33. The stake represents ﹤0.01% of the portfolio and ranks #2326 among its holdings.

171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

Twin Peaks Wealth Advisors held 24 shares of Akebia Therapeutics worth $33 as of Q1 2026.
Akebia Therapeutics was a new Twin Peaks Wealth Advisors position in Q1 2026.
Akebia Therapeutics made up ﹤0.01% of Twin Peaks Wealth Advisors's portfolio in Q1 2026, its #2326 holding.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q1 2026, filed 8 May 2026.